Table 2 Summary findings for the extended cost–effectiveness analysis of the 75% increase in the price of cigarette in Iran, over 60 years
Quintiles | I (poorest) | II | III | IV | V (richest) | Total |
|---|---|---|---|---|---|---|
Premature deaths averted | 21,559 (11%) | 41,822 (21%) | 47,646 (24%) | 47,507 (24%) | 39,973 (20%) | 198,507 |
Years of life gained | 205,869 (11%) | 392,289 (21%) | 444,837 (24%) | 446,292 (24%) | 373,293 (20%) | 1,862,580 |
Expenditures on tobacco-related disease treatment averted (2017; in $US) | 17,582,885 (9%) | 38,740,848 (20%) | 47,973,669 (24%) | 48,312,051 (25%) | 43,870,212 (22%) | 196,479,664 |
Total OOP savings (2017; in $US) | 7,208,983 (9%) | 15,883,747 (20%) | 19,669,204 (24%) | 19,807,941 (25%) | 17,986,787 (22%) | 80,556,662 |
Additional tax revenues from excise tax (2017; in $US) | 123,410,713 (12%) | 169,421,522 (17%) | 238,482,157 (24%) | 254,234,088 (25%) | 214,386,022 (21%) | 999,934,501 |
Change in annual expenditures on cigarette (2017; in $US) % of individual income | 33,830,736 (1.95%) | 46,443,738 (1.47%) | 59,620,539 (1.31%) | 57,278,036 (0.85%) | 78,318,141 (0.89%) | 275,491,189 |
Poverty cases averted | 5418 (0.5%) | 11,826 (0.9%) | 0 | 0 | 0 | 17,244 |
No. of cases of catastrophic expenditure averted | 12,912 (1.2%) | 28,452 (2.2%) | 14,922 (1.1%) | 0 | 0 | 56,287 |